A Phase III Multicenter, Double-Blind, Randomized, Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin) in Pediatric Subjects aged 10-17 years with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy